Da øgningen ligger inden for den normale variabilitet for biotilgængeligheden af ibandronsyre, anses dosisjustering ikke for nødvendig, når Bonviva administreres sammen med H2- antagonister eller andre aktive substanser, som øger gastrisk pH.
However, since this increase is within the normal variability of the bioavailability of ibandronic acid, no dose adjustment is considered necessary when Bonviva is administered with H2- antagonists or other active substances which increase gastric pH.